Carbon monoxide and a change of heart.
Carbon monoxide and a change of heart.
复制标题
DOI：
10.1016/j.redox.2021.102183
复制
发表时间：
2021-12
期刊：
影响因子：
11.4
通讯作者：
Otterbein LE
中科院分区：
文献类型：
--
作者：
Chu LM;Shaefi S;Byrne JD;Alves de Souza RW;Otterbein LE
一氧化碳与心脏之间的关系已在临床和临床前环境中得到广泛研究。美国食品和药物管理局 (FDA) 在提出临床试验建议以评估这种气体递质在各种疾病环境中的功效时，高度关注一氧化碳对心脏的不良影响。这篇综述概述了审查 FDA 在考虑 CO 临床测试时采取的行动的基本原理，并将其与不断积累的数据进行对比，这些数据清楚地表明 CO 不仅可以安全使用，而且在临床相关的小型和大型动物模型中具有有效的心脏保护作用。第一阶段和第二阶段临床试验的数据表明，一氧化碳对心脏有害，因此需要像提议用于人类的任何其他物质一样对其进行重新定义和评估。二十多年前，生理学和医学专家嘲笑二氧化碳可以作为一种有益分子的信念。与所有设计用于人类的药物一样，仔细的药理学和安全性至关重要，但在缺乏数据的情况下继续基于长期存在的教条阻碍进展是不适当的。现在，CO 正在使用创新的输送方法进行多项临床试验，并已被证明是安全的。基于令人信服的临床前数据，我们希望它将继续得到评估并最终被批准为一种有效的治疗方法。
The relationship between carbon monoxide and the heart has been extensively studied in both clinical and preclinical settings. The Food and Drug Administration (FDA) is keenly focused on the ill effects of carbon monoxide on the heart when presented with proposals for clinical trials to evaluate efficacy of this gasotransmitter in a various disease settings. This review provides an overview of the rationale that examines the actions of the FDA when considering clinical testing of CO, and contrast that with the continued accumulation of data that clearly show not only that CO can be used safely, but is potently cardioprotective in clinically relevant small and large animal models. Data emerging from Phase I and Phase II clinical trials argues against CO being dangerous to the heart and thus it needs to be redefined and evaluated as any other substance being proposed for use in humans. More than twenty years ago, the belief that CO could be used as a salutary molecule was ridiculed by experts in physiology and medicine. Like all agents designed for use in humans, careful pharmacology and safety are paramount, but continuing to hinder progress based on long-standing dogma in the absence of data is improper. Now, CO is being tested in multiple clinical trials using innovative delivery methods and has proven to be safe. The hope, based on compelling preclinical data, is that it will continue to be evaluated and ultimately approved as an effective therapeutic.
登录
查看更多内容
影响因子：
10
作者：
Brinchmann BC;Skuland T;Rambøl MH;Szoke K;Brinchmann JE;Gutleb AC;Moschini E;Kubátová A;Kukowski K;Le Ferrec E;Lagadic-Gossmann D;Schwarze PE;Låg M;Refsnes M;Øvrevik J;Holme JA
通讯作者：
Holme JA
影响因子：
20.1
作者：
Clark, JE;Naughton, P;Motterlini, R
通讯作者：
Motterlini, R
影响因子：
15.9
作者：
COBURN, RF;WILLIAMS, WJ;KAHN, SB
通讯作者：
KAHN, SB
影响因子：
39.2
作者：
ANDERSON, EW;ANDELMAN, RJ;KNELSON, JH
通讯作者：
KNELSON, JH
影响因子：
4.6
作者：
Carmona, Francisco J.;Jimenez-Amezcua, Ignacio;Barea, Elisa
通讯作者：
Barea, Elisa